Robust clinical trial data are proving to be fundamental in shaping investor confidence and driving strategic decisions in the biotechnology sector. Between 2015 and 2020 alone, biotech investments have heavily favored companies with advanced clinical-stage candidates, underscoring the close link between science and capital.
Evaluating a biotech company’s clinical pipeline and trial maturity is often more insightful than financials alone. At Axcellant, we see this impact firsthand: from designing robust Phase II studies to supporting pivotal Phase III trials, we’re helping biotech innovators translate scientific promise into commercial value.
Curious about how clinical strategy can align with business success? Let’s continue the conversation.
Read the full article (in Polish) here.
3 Questions with: Prof. Piotr Słomka Large language models are entering nuclear cardiology at a pace that makes the usual…
How Axcellant helped a diagnostic study overcome isotope supply, manufacturing, and logistics constraints In radiopharmaceutical development, we often say that…
Europe’s clinical trials market is entering a more practical phase in its approach to competitiveness. With the Clinical Trials Regulation…
Copyright @ 2026 Axcellant